Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.
Trial enrolled 164 adults who had failed one prior CGRP preventive treatment
The 24-week, open-label, multicenter trial (NCT06701526) was conducted in the United States and enrolled 164 adults with at least eight monthly migraine days who had previously used either a subcutaneous anti-CGRP monoclonal antibody or a preventive gepant, but had not received eptinezumab. Participants started on 100 mg of eptinezumab, escalating to 300 mg at week 12, with 147 receiving both infusions; 84% (138/164) completed the trial.
Primary endpoint improved from 44% at week 12 to 60% at week 24
At week 12, 44% of remaining participants reported being 'much improved' or 'very much improved' on the Patient Global Impression of Change (PGIC) scale. By week 24, the trial's primary endpoint, that figure rose to 60%. Secondary measures included reductions in monthly migraine days, acute medication use, and patient-reported burden metrics such as MIDAS and goal attainment scaling.
No new safety signals emerged in patients who had failed prior CGRP therapy
Lundbeck stated eptinezumab was generally well tolerated in this population, with no new safety signals identified. Tarek Samad, Executive Vice President and Head of Research and Development at Lundbeck, said the results address a clinically relevant question about treatment sequencing for patients with substantial migraine burden after failing a prior CGRP-targeting therapy.
Evidence gap targeted as real-world discontinuation rates reach 40-45%
THRIVE is positioned as the first interventional trial specifically designed to evaluate eptinezumab outcomes in patients who previously had an inadequate response to a CGRP-targeting preventive therapy. Lundbeck cited real-world studies showing anti-CGRP monoclonal antibodies and preventive gepants carry discontinuation rates of approximately 40-45%, with inadequate effectiveness among the leading causes.
Full data set will be submitted to scientific congresses and peer review
Lundbeck said complete THRIVE results, including secondary endpoint data on migraine day reductions and burden measures, will be submitted for presentation at a future scientific congress and for publication in a peer-reviewed journal. Eptinezumab holds FDA approval since February 2020 and European Commission marketing authorization since January 2022, and is currently launched in more than 30 markets worldwide.